HIV-1 Infected Adult Subjects With HIV-associated Neurocognitive Disorders Despite Effective Antiretroviral Therapy

NACompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

November 1, 2011

Primary Completion Date

June 29, 2012

Study Completion Date

July 26, 2016

Conditions
HIV-1-infectionHIV Associated Neurocognitive Disorder
Interventions
OTHER

Validation of Charter score for the CNS diffusion of antiretroviral drugs

IHFB001 (Neuroplustrois) is a pilot study, phase IV, open-label, multicenter in Ile-de-France region, trying to demonstrate the improvement of cognitive change after treatment characterized by its better diffusion in the central nervous system. The characteristics of the change in treatment are (Cn - Ci) ≥ 3 and Cn ≥ 9, where Cn is the Charter score of the new treatment and Ci the Charter score of the initial treatment.

Trial Locations (12)

77000

Centre Hospitalier Marc Jacquet, Melun

78100

Centre Hospitalier Intercommunal de Poissy Germain en Laye, Saint-Germain-en-Laye

78150

Hôpital Mignot Centre Hospitalier de Versailles, Chesnay

91640

Centre Hospitalier de Bligny, Briis-sous-Forges

92150

Hôpital Foch, Suresnes

92300

Institut Hospitalier Franco- Britannique, Levallois-Perret

92380

Hôpital Raymond Poincaré, Garches

93200

Hôpital Delafontaine, Saint-Denis

93602

Hôpital Intercommunal Robert Ballanger, Aulnay-sous-Bois

95100

Hôpital d'Argenteuil, Argenteuil

95300

Centre Hospitalier René Dubois, Pontoise

95500

Centre Hospitalier de Gonesse, Gonesse

All Listed Sponsors
collaborator

Hospital Ambroise Paré Paris

OTHER

lead

Hôpital Franco-Britannique-Fondation Cognacq-Jay

OTHER

NCT04266002 - HIV-1 Infected Adult Subjects With HIV-associated Neurocognitive Disorders Despite Effective Antiretroviral Therapy | Biotech Hunter | Biotech Hunter